RxDoctor Payments Data

Paul Ikemire, MD

General Practice · New Orleans, LANPI 1477870210

Payments from drug & device makers

$606in general payments, 2019–2025

Across 32 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$295
  • AstraZeneca$167
  • AbbVie$74
  • Boehringer Ingelheim$26
  • E.r. Squibb & Sons, L.L.C.$18
  • Pfizer$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$59198%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$606 in reported general payments places this provider in the 70th percentile of 1,221 general practice providers in Louisiana.

See all general practice providers in Louisiana

Medicare billing

Part B allowed, 2024
$9,499
Medicare patients
19
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide317$312,284
Combivent RespimatIpratropium/Albuterol Sulfate212$105,064
HumiraAdalimumab11$97,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$81,631
TrulicityDulaglutide73$74,578
CreonLipase/Protease/Amylase54$67,538
JanuviaSitagliptin Phosphate51$61,206
TradjentaLinagliptin77$53,871
JardianceEmpagliflozin49$42,141
LinzessLinaclotide56$41,089
EliquisApixaban41$37,581
SymbicortBudesonide/Formoterol Fumarate110$26,093
Atrovent HfaIpratropium Bromide52$25,167
MounjaroTirzepatide21$22,499
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,083$21,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Creon, Linzess$74$206,036121 claims
Boehringer IngelheimCombivent Respimat, Tradjenta, Jardiance$26$201,076338 claims
GSKTrelegy Ellipta, Anoro Ellipta$295$95,565156 claims
PfizerEliquis, Premarin$14$52,675106 claims
AstraZenecaSymbicort$167$26,093110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,221 general practice providers in Louisiana.

Other general practice in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →